Can Mesothelioma Present as a Brain Tumor?
Yes, mesothelioma can metastasize to the brain and present as a brain tumor, though this is rare, occurring in approximately 3-6% of patients with malignant pleural mesothelioma. 1, 2
Epidemiology and Clinical Context
Brain metastases from mesothelioma are uncommon but increasingly recognized, particularly in the modern treatment era. The 1- and 2-year cumulative rates of brain metastases are 4.0% and 5.3%, respectively 1. Importantly, recent data suggest that patients treated with immunotherapy have a significantly higher incidence of brain metastases (4%) compared to those receiving chemotherapy alone (0%) 2. This represents a critical shift in clinical practice—as patients live longer with improved systemic therapies, the brain becomes a more frequent site of metastatic disease.
Key Risk Factors for Brain Metastases:
- Age <65 years (odds ratio 5.83) 1
- Advanced stage disease (IMIG stage IV, odds ratio 1.69) 1
- Exposure to immunotherapy (4% vs 0% with chemotherapy) 2
Clinical Presentation
When mesothelioma metastasizes to the brain, patients typically present with:
- Altered mental status and confusion
- Focal neurological deficits (e.g., expressive aphasia)
- Seizures
- Headaches
- Symptoms related to mass effect and vasogenic edema 3
Critical pitfall: Unlike lung adenocarcinoma, CNS metastases are uncommon in mesothelioma, so routine brain imaging is not recommended in asymptomatic patients 4. However, any patient with mesothelioma presenting with unexplained neurological symptoms should undergo immediate brain MRI 5.
Diagnostic Considerations
Brain imaging should be pursued when:
- Neurological symptoms develop in a patient with known mesothelioma
- Before initiating immunotherapy in patients with pleural mesothelioma (given the increased risk) 2
- In younger patients (<65 years) with advanced stage disease 1
The diagnosis requires tissue confirmation when possible, as mesothelioma brain metastases can be difficult to distinguish from other pathology. Immunoperoxidase stains are essential for confirming mesothelial lineage 6.
Prognosis
The prognosis for mesothelioma patients who develop brain metastases is poor:
- Median overall survival from brain metastasis diagnosis: 95 days (range 16-1,025 days) 2
- Median overall survival is significantly worse than patients without brain metastases (6.5 vs 11.0 months) 1
Treatment Approach
When brain metastases are confirmed, treatment options mirror those for other solid tumor brain metastases 5, 7:
For 1-3 Brain Metastases:
- Stereotactic radiosurgery (SRS) alone is the recommended initial therapy 8, 9, 10
- Surgical resection should be considered for:
For ≥5 Brain Metastases:
- Whole brain radiation therapy (WBRT) is recommended 8
- Consider memantine and hippocampal avoidance if no hippocampal lesions and expected survival ≥4 months 9
Supportive Care:
- Dexamethasone 16 mg/day during definitive therapy with rapid taper as symptoms allow 8
- Anticonvulsants only for patients who present with seizures (not prophylactically) 5
Important Clinical Caveat
Despite achieving local tumor control with SRS or surgery, systemic disease progression typically determines overall survival 10, 11. Conventional treatment options (surgical resection and brain radiation) have limited effectiveness in improving long-term outcomes for mesothelioma brain metastases 11. The median survival remains approximately 3 months even with aggressive local therapy 11, 2.
Emerging Considerations
With the increasing use of immunotherapy for mesothelioma, clinicians should maintain heightened awareness for brain metastases in this population 2. Consider baseline brain imaging before initiating immunotherapy in high-risk patients (younger age, advanced stage disease), though this is not yet a guideline recommendation.